OverviewSuggest Edit

Moleculin Biotech, Inc. is preclinical and clinical-stage pharmaceutical company focused on the development of game-changing anti-cancer drug candidates. The Company's lead product candidate is liposomal Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia. Unlike current therapies that risk cardiotoxicity and can have their effectiveness limited due to multidrug resistance, Annamycin appears capable of avoiding both of these problems and has already demonstrated the ability to save lives in clinic.

TypePublic
Founded2006
HQHouston, US
Websitemoleculin.com

Latest Updates

Employees (est.) (Dec 2018)9(+350%)
Share Price (Jun 2019)$1.2

Key People/Management at Moleculin Biotech

Donald Picker

Donald Picker

Chief Scientific Officer
Robert Shepard

Robert Shepard

Chief Medical Officer - Hematology
Sandra Silberman

Sandra Silberman

Chief Medical Officer - New Products
Jonathan P. Foster

Jonathan P. Foster

CFO
Show more

Moleculin Biotech Office Locations

Moleculin Biotech has an office in Houston
Houston, US (HQ)
2575 W Bellfort Ave #333
Show all (1)

Moleculin Biotech Financials and Metrics

Moleculin Biotech Revenue

USD

Net income (FY, 2018)

(11.9m)

EBIT (FY, 2018)

(15.0m)

Market capitalization (10-Jun-2019)

52.9m

Closing stock price (10-Jun-2019)

1.2

Cash (31-Dec-2018)

7.1m
Moleculin Biotech's current market capitalization is $52.9 m.
Annual
USDFY, 2016FY, 2017FY, 2018

General and administrative expense

2.4m4.1m5.2m

R&D expense

1.5m4.5m9.7m

Operating expense total

3.9m8.7m15.0m

Depreciation and amortization

6.2k18.0k68.0k
Quarterly
USDQ2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

General and administrative expense

618.0k924.0k848.0k800.0k1.3m1.4m2.6m

R&D expense

104.8k496.7k683.0k515.0k1.1m1.2m5.5m

Operating expense total

723.5k1.4m1.5m1.3m2.4m2.6m8.1m

Depreciation and amortization

652.0977.04.0k5.0k5.0k8.0k15.0k
Annual
USDFY, 2016FY, 2017FY, 2018

Cash

5.0m7.7m7.1m

Current Assets

5.2m8.3m8.0m

Total Assets

16.4m19.5m19.6m

Accounts Payable

1.0m810.0k1.2m
Quarterly
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

Cash

259.7k7.2m6.2m8.9m9.3m8.7m13.1m11.7m

Current Assets

7.6m6.4m9.2m10.1m9.5m13.7m12.9m

Total Assets

289.7k18.7m17.6m20.3m21.2m20.6m24.9m24.1m

Accounts Payable

363.0k721.1k945.0k858.0k645.0k1.1m570.0k1.7m
Annual
USDFY, 2016FY, 2017FY, 2018

Net Income

(3.9m)(9.8m)(11.9m)

Depreciation and Amortization

6.2k18.0k68.0k

Accounts Payable

(41.1k)411.0k436.0k

Cash From Operating Activities

(3.8m)(7.3m)(12.2m)
Quarterly
USDQ3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

Net Income

(2.5m)(329.0k)(3.8m)(6.6m)(1.9m)(7.1m)

Depreciation and Amortization

1.6k4.0k8.0k13.0k8.0k15.0k

Accounts Payable

(146.8k)49.0k(160.0k)285.0k(239.0k)866.0k

Cash From Operating Activities

(2.6m)(1.4m)(3.3m)(4.9m)(2.8m)(6.3m)
USDY, 2018

Financial Leverage

1.4 x
Show all financial metrics

Moleculin Biotech Online and Social Media Presence

Embed Graph

Moleculin Biotech News and Updates

Moleculin Biotech, Inc. Reports Financial Results for the First Quarter Ended March 31, 2019

HOUSTON, May 14, 2019 /PRNewswire/ -- Moleculin Biotech, Inc. (NASDAQ: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced its financial results for the first quarter...

Thinking about buying stock in Cronos Group Inc., Hasbro Inc., Moleculin Biotech Inc., Regional Health Properties Inc., or Twitter Inc.?

NEW YORK, April 23, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CRON, HAS, MBRX, RHE, and TWTR. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. ...

Moleculin Biotech, Inc. to Present at the Oppenheimer 29th Annual Healthcare Conference and the 31st Annual ROTH Conference

HOUSTON, March 18, 2019 /PRNewswire/ -- Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a clinical-stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System...

Moleculin Biotech, Inc. Reports Financial Results for the Year Ended December 31, 2018

HOUSTON, Feb. 21, 2019 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a clinical-stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System on beh…

Moleculin Biotech, Inc. Reports Financial Results for the Third Quarter Ended September 30, 2018

HOUSTON, Nov. 13, 2018 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System on beh…

Moleculin Biotech, Inc. Reports Financial Results for the Second Quarter Ended June 30, 2018

HOUSTON, Aug. 13, 2018 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System on beh…

Moleculin Biotech Blogs

Moleculin Announces its Sponsored Research at MD Anderson Cancer Center Has Resulted in the Filing of Patent Protection for New Discovery

HOUSTON, Sept. 16, 2019 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced its sponsored research at MD Anderson Cancer Center h…

Moleculin Biotech, Inc. Reports Financial Results for the Second Quarter Ended June 30, 2019

HOUSTON, Aug. 16, 2019 /PRNewswire/ -- Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced its financial results for the second quarter ended Jun…

Moleculin Announces Breakthrough Discovery: WP1066 Potentially Capable of Immune Reprogramming in Glioblastoma Animal Models

Data to be presented at the Inaugural Conference on Brain Metastases, August 16-17, 2019 HOUSTON, Aug. 6, 2019 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly…

Moleculin Announces Annamycin in Acute Myeloid Leukemia in Poland Advances to 3rd Cohort

HOUSTON, July 18, 2019 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced additional positive interim safety and efficacy data f…

Moleculin Files for New Patents for Annamycin After Receiving FDA Approval of Fast Track Designation

HOUSTON, July 10, 2019 /PRNewswire/ -- Moleculin Biotech, Inc. (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced it has filed new patents covering the production and re…

US Biopharma Company Undertakes Anti-Cancer Clinical Trials in Poland, First Patient Showing Positive Initial Treatment

Moleculin quickly recruited qualified patients and started trials for two of its portfolio drugs to supplement US efforts. HOUSTON, April 29, 2019 /PRNewswire/ -- A small public company with 6 highly promising anti-cancer drugs in the pipeline is augmenting US clinical trials with trials in Polan…
Show more

Moleculin Biotech Frequently Asked Questions

  • When was Moleculin Biotech founded?

    Moleculin Biotech was founded in 2006.

  • Who are Moleculin Biotech key executives?

    Moleculin Biotech's key executives are Donald Picker, Robert Shepard and Sandra Silberman.

  • How many employees does Moleculin Biotech have?

    Moleculin Biotech has 9 employees.

  • Who are Moleculin Biotech competitors?

    Competitors of Moleculin Biotech include Vivace Therapeutics, Merrimack Pharmaceuticals and CytomX Therapeutics.

  • Where is Moleculin Biotech headquarters?

    Moleculin Biotech headquarters is located at 2575 W Bellfort Ave #333, Houston.

  • Where are Moleculin Biotech offices?

    Moleculin Biotech has an office in Houston.

  • How many offices does Moleculin Biotech have?

    Moleculin Biotech has 1 office.